JP2022548057A5 - - Google Patents

Info

Publication number
JP2022548057A5
JP2022548057A5 JP2022516173A JP2022516173A JP2022548057A5 JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5 JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5
Authority
JP
Japan
Prior art keywords
nrg1
amino acid
acid sequence
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548057A (ja
JP7708741B2 (ja
Filing date
Publication date
Priority claimed from GBGB1913079.8A external-priority patent/GB201913079D0/en
Application filed filed Critical
Publication of JP2022548057A publication Critical patent/JP2022548057A/ja
Publication of JP2022548057A5 publication Critical patent/JP2022548057A5/ja
Priority to JP2025112447A priority Critical patent/JP2025143396A/ja
Application granted granted Critical
Publication of JP7708741B2 publication Critical patent/JP7708741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516173A 2019-09-11 2020-09-10 Her3抗原結合性分子を使用したがんの処置および予防 Active JP7708741B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112447A JP2025143396A (ja) 2019-09-11 2025-07-02 Her3抗原結合性分子を使用したがんの処置および予防

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1913079.8A GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules
GB1913079.8 2019-09-11
PCT/EP2020/075319 WO2021048274A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112447A Division JP2025143396A (ja) 2019-09-11 2025-07-02 Her3抗原結合性分子を使用したがんの処置および予防

Publications (3)

Publication Number Publication Date
JP2022548057A JP2022548057A (ja) 2022-11-16
JP2022548057A5 true JP2022548057A5 (cg-RX-API-DMAC7.html) 2023-09-19
JP7708741B2 JP7708741B2 (ja) 2025-07-15

Family

ID=68241208

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516173A Active JP7708741B2 (ja) 2019-09-11 2020-09-10 Her3抗原結合性分子を使用したがんの処置および予防
JP2025112447A Pending JP2025143396A (ja) 2019-09-11 2025-07-02 Her3抗原結合性分子を使用したがんの処置および予防

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112447A Pending JP2025143396A (ja) 2019-09-11 2025-07-02 Her3抗原結合性分子を使用したがんの処置および予防

Country Status (16)

Country Link
US (3) US11208498B2 (cg-RX-API-DMAC7.html)
EP (2) EP3943509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7708741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086554A (cg-RX-API-DMAC7.html)
CN (2) CN113347994B (cg-RX-API-DMAC7.html)
AU (1) AU2020347473B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004474A8 (cg-RX-API-DMAC7.html)
CA (1) CA3149853A1 (cg-RX-API-DMAC7.html)
DK (1) DK3818086T3 (cg-RX-API-DMAC7.html)
ES (1) ES2896921T3 (cg-RX-API-DMAC7.html)
GB (1) GB201913079D0 (cg-RX-API-DMAC7.html)
MX (1) MX2022002977A (cg-RX-API-DMAC7.html)
PL (1) PL3818086T3 (cg-RX-API-DMAC7.html)
PT (1) PT3818086T (cg-RX-API-DMAC7.html)
TW (1) TWI883044B (cg-RX-API-DMAC7.html)
WO (1) WO2021048274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3023551T3 (en) 2016-03-25 2025-06-02 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
AU2018241881B2 (en) 2017-03-27 2024-10-10 Biomunex Pharmaceuticals Stable multispecific antibodies
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CN114790462B (zh) * 2021-01-25 2023-10-31 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向bcma的嵌合抗原受体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
WO2022192534A1 (en) * 2021-03-11 2022-09-15 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
TW202313972A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 新nrg1融合物、融合接合處及檢測彼等之方法
WO2022255869A2 (en) * 2021-06-03 2022-12-08 Merus N.V. Liquid biopsy assays for detecting nrg1 fusion polynucleotides
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
JP2024529141A (ja) 2021-08-13 2024-08-01 ハミングバード・バイオサイエンス・プライベート・リミテッド Her3抗原結合性分子を使用したがんの処置および予防
CN118541395A (zh) * 2021-09-03 2024-08-23 癌症研究科技有限公司 用her3抗原结合分子治疗和预防癌症
CN116333118B (zh) * 2021-12-16 2024-04-19 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
IL315262A (en) * 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
WO2024121226A1 (en) 2022-12-07 2024-06-13 Hummingbird Bioscience Pte. Ltd. Combination for treatment and prevention of cancer
CN120857946A (zh) 2023-01-03 2025-10-28 蜂鸟生物科技私人有限公司 Her3结合抗体-药物缀合物
KR20260026009A (ko) 2023-04-06 2026-02-25 허밍버드 바이오사이언스 피티이. 엘티디. Her3 항원 결합 분자를 이용한 암의 치료 및 예방
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025057173A2 (en) * 2023-09-14 2025-03-20 B.G. Negev Technologies And Applications Ltd. Ligand-based chimeric antigen receptors and uses thereof
CN122206706A (zh) 2023-09-15 2026-06-12 蜂鸟生物科技私人有限公司 使用her3结合分子治疗和预防癌症

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
KR20150036824A (ko) * 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10239951B2 (en) * 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US20160319253A1 (en) 2013-12-19 2016-11-03 National Cancer Center Novel fusion genes as factors responsible for gastric cancer
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ NRG1融合遺伝子を有する細胞の処置における使用のためのErbB-2及びErbB3結合二重特異性抗体
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Similar Documents

Publication Publication Date Title
JP2022533957A5 (cg-RX-API-DMAC7.html)
Nishioka et al. Lysyl oxidase: from basic science to future cancer treatment
IL270852A (en) Molecules that bind at the site of egfr and c – met - fibronectin type iii
Yaffee et al. Review of systemic therapies for locally advanced and metastatic rectal cancer
Monk et al. Anti-angiogenesis agents in metastatic or recurrent cervical cancer
JP2022088662A5 (cg-RX-API-DMAC7.html)
Wang et al. Molecular mechanisms of chemoresistance in oral cancer
EP4512478A3 (en) Treatment of cancer
JP2011521618A5 (cg-RX-API-DMAC7.html)
RU2007132876A (ru) Антитела к dr5 и их применения
JP2017503480A5 (cg-RX-API-DMAC7.html)
IL292193B2 (en) Anti-b7-h1 antibodies for treating tumors
RU2019143403A (ru) Комбинированные терапии для лечения онкологических заболеваний
JP2024536719A5 (cg-RX-API-DMAC7.html)
Li et al. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
Gafton et al. Hepatocellular carcinoma: insight in the biological treatment beyond sorafenib
Le Bourhis et al. Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications
JP2022551495A5 (cg-RX-API-DMAC7.html)
RU2015154985A (ru) Способы лечения рака
RU2019134769A (ru) Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения
JP2025508695A5 (cg-RX-API-DMAC7.html)
Akent'eva et al. Effects of RHAMM/HMMR-selective peptides on survival of breast cancer cells
Rajabi et al. DLEU1 as a key regulator in glioblastoma: A review of ferroptosis resistance, tumor microenvironment interactions, and emerging RNA-based therapeutic strategies
Chetia et al. From unearthing to an intriguing cancer-fighting target: the human BCL-2 promoter G-quadruplex and i-motif.
Radford et al. Targeted and immunotherapy approaches in HER2-positive gastric and gastroesophageal junction adenocarcinoma: a new era